



### **1803\_01: Cupron Inc. – Cupron Medical Textiles**

Evaluated by the Rapid Review panel

17 April 2018

**Evaluation Level E3:** Basic research and development has begun and the product may have value; the product requires head-to-head trials against existing available products to demonstrate improved efficiency or efficacy in improving infection prevention and control interventions to reduce healthcare associated infection.

- Cupron Inc. has developed a patented platform technology, which permanently impregnates copper oxide particles in polymeric textile fibres, endowing them with potent biocidal properties. The fibres are then used for the mass production of medical textiles such as sheets, pillowcases, patient robes/pyjamas, towels and blankets.

**Evaluation Disclaimer:** The RRP does not formally review cost-effectiveness or implementation barriers during its evaluation of products; these factors may be considered in a separate process. It is the responsibility of the applicant to carry out any further required development, including trials, cost-effectiveness assessments or product implementation within the NHS. All statements comparing the efficiency or efficacy of products are in the context of products available for use to the NHS at the date of evaluation.